Perspective

Customization of therapy for gastroesophageal adenocarcinoma patients

Dilsa Mizrak Kaya, Kazuto Harada, Fatemeh G. Amlashi, Maria Vasilakopoulou, Jaffer A. Ajani*

Department of Gastrointestinal Medical Oncology, The University of Texas M.D. Anderson Cancer Center, Houston, TX 77030, USA

Received 12 December 2017
Available online 13 March 2018

Abstract

Gastroesophageal adenocarcinomas (GEACs) remain a global health problem. These are most often diagnosed at advanced stage and the estimated 5-year relative survival rate is about 5%. Although cure is not possible for patients with advanced GEAC, systemic therapy (chemotherapy or biochemotherapy) can palliate symptoms, improve survival and provide a better quality of life. One of the most promising options for some patients with advanced stage GEAC is immunotherapy, which can result in durable responses. Numerous phase III trials evaluating targeted therapies in different lines are ongoing and it is hoped that better biomarkers will emerge to identify patients who can benefit from targeted agents and immunotherapy in the future. Surgery remains as the corner stone for localized GEAC and adjunctive therapies can increase the survival rates by about 10%. The high toxicity and low completion rates of adjuvant therapy led to the strategies of preoperative treatment. With the results of ongoing pre-operative therapy trials we will be able to determine the optimal adjunctive approach for resectable GEAC.

© 2018 Chinese Medical Association. Production and hosting by Elsevier B.V. on behalf of KeAi Communications Co., Ltd. This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).

Keywords: Therapy; Gastroesophageal adenocarcinoma; Esophageal adenocarcinoma; Gastric adenocarcinoma

Introduction

Gastroesophageal adenocarcinomas (GEACs), originating from esophagus, esophagogastric junction (EGJ) and stomach, remain as a worldwide health problem with an estimated 1,407,400 new cases and 1,123,300 deaths in 2012, globally.¹ These are highly lethal cancer types and constitute about 15% of all cancer related deaths.⁴ In recent decades, location of esophageal carcinoma has shifted from proximal to distal location and gastric cancer has migrated from distal location to proximal one in the West.⁴ This trend is also found in Asia and South America.⁴
Changes in the locations are mostly related to increased incidence of obesity, gastroesophageal reflux disease (GERD), Barrett’s esophagus and decreased incidence of H. Pylori infection (Fig. 1).3–6 This trend is occurring in other regions as well and EGJ adenocarcinoma (adenocarcinomas that have their epicenter in the 10-cm segment encompassing the 5 cm above and 5 cm below EGJ) constitutes the major burden of GEACs.2 Selecting appropriate therapy for GEAC may be possible after accurate stage is determined and patients discuss with a multidisciplinary team consisting of medical oncologists, surgeons, radiation oncologists, radiologists, pathologists and supportive care specialists. With the American Joint Committee on Cancer (AJCC) 8th edition, staging and definition of esophageal, EGJ and gastric cancers are more clear.7 According to the AJCC 8th edition, a tumor involving the EGJ with its epicenter ≤2 cm below EGJ, should be classified as esophageal cancer, all others below EGJ should be classified as gastric cancer. This classification is important to deciding on the right surgical approach. Surgery is the most important component of treatment for localized GEACs but unfortunately most of the patients are diagnosed with an advanced stage.3,4 For intramucosal GEACs, minimally invasive approaches like endoscopic mucosal resection (EMR) and endoscopic submucosal dissection (ESD) can be alternatives to surgery in experienced centers.8,9

**Therapy for localized esophageal adenocarcinoma**

Surgery remains as the corner stone treatment for operable esophageal adenocarcinoma (EAC). However, the reported median overall survival (OS) durations for patients treated only with surgery were less than 18 months in different trials.10,11 Therefore, preoperative strategies have become popular. It was shown that post-treatment pathologic stage is the best prognosticator of survival for EAC and the OS was significantly better for patients with no residual carcinoma.12

Radiation Therapy Oncology Group trial 8911 (RTOG 8911) compared surgery alone with preoperative cisplatin plus fluorouracil (CF) in localized esophageal and EGJ tumors mostly composed of adenocarcinoma.10,13 In this trial, adding CF to surgery did not prolong the survival [16.1 months for surgery-only group and 14.9 months for pre-operative CF group; hazard ratio (HR), 1.07; 95% CI: 0.87–1.32; P = 0.53] and margin negative (R0) resection rates were similar for both groups (59% for surgery-only group and 62% for pre-operative CF group). However, a similar trial conducted by the United Kingdom Medical Research Council (OE02)11,14 demonstrated longer OS for pre-operative CF patient group (13.3 months for surgery-only group and 16.8 months for pre-operative CF group; HR, 0.79; 95% CI: 0.67–0.93; P = 0.004) and R0 resection rates were parallel (53% for surgery-only group and 60% for pre-operative CF group) with the rates reported by RTOG8911. The long-term follow-up of both of these studies showed that performing an R0 resection is the most important factor related with longer OS.13,14 A recent study, OE05, compared two cycles of pre-operative CF with four cycles of pre-operative epirubicin, cisplatin, and capecitabine (ECX).15 There was no survival benefit with intensified therapy (median OS; 23.4 months in the CF group and 26.1 months in the ECX group; HR, 0.90; 95% CI: 0.77–1.05; P = 0.19). Moreover, the number of patients that could complete the preoperative therapy was significantly higher in CF than ECX group (96% of CF group vs. 81% of ECX group; P < 0.0001) and more patients discontinued the therapy due to toxicities in ECX group (10% vs. 2%).

In a study from France, peri-operative CF was compared with surgery alone in a patient group mostly consisting of patients with esophageal and EGJ adenocarcinoma.16 It resulted in a longer OS benefit in favor of the peri-operative treatment group (HR, 0.69; 95% CI: 0.50–0.95; P = 0.02). However, only 50% of the peri-operative treatment group could receive the planned post-operative treatment. This trial was
terminated early and had small number of patients for analysis.

The importance of R0 surgery to prognosis of localized EAC and the desire to reach higher local control rates, led to the evaluation of pre-operative chemoradiation for localized EAC. Earlier small studies had inconsistent results. However, meta-analyses supported pre-operative chemoradiation. In 2012, van Hagen et al. reported the “Chemoradiotherapy for Oesophageal Cancer Followed by Surgery Study” (CROSS) with 366 patients. The R0 resection rate was higher (92% of patients in the chemoradiotherapy—surgery group vs. 69% in the surgery-only group, \( P < 0.001 \)) and the median OS was longer (49.4 months vs. 24 months; \( HR, 0.657; \) 95% CI: 0.495–0.871; \( P = 0.003 \)) for pre-operative chemoradiation group. After CROSS, pre-operative chemoradiation followed by surgery has been the most commonly strategy for localized esophageal carcinoma. However, CROSS selected the best patient population and advantage for EAC is marginal.

Limited number of studies compared the two accepted treatment approaches, namely pre-operative chemotherapy and pre-operative chemoradiation, for localized EAC. A phase III study evaluated the effect of adding chemoradiation to induction chemotherapy before surgery. This study was closed early due to poor accrual and could not meet the primary endpoint of OS. However, chemoradiation group had a higher pathologic complete response rate (15.6% vs. 2%) and long-term follow-up demonstrated longer local progression-free survival (PFS) from chemoradiation (\( HR, 0.37; \) 95% CI: 0.16–0.85; \( P = 0.01 \)). In a phase II study, Burmeister et al. compared pre-operative CF with pre-operative chemoradiation. There was no survival benefit for chemoradiation group but the pathological response rate was significantly higher in chemoradiation group. These studies have a number of shortcomings. Another phase II trial aimed to increase pathologic complete response rate by adding induction chemotherapy to pre-operative chemoradiation but did not reach a significant outcome (13% vs. 26%, \( P = 0.094 \)). A recently reported multicenter trial comparing pre-operative chemotherapy with pre-operative chemoradiation met its primary endpoint of histologic complete response. Pathologic complete response rate was 28% after pre-operative chemoradiation and it was only 9% after pre-operative chemotherapy. However, there was no OS difference between the two arms. Three phase III studies comparing pre-operative chemoradiation with peri-operative regimens for resectable EAC are ongoing. The first is “Perioperative Chemotherapy Compared To Neoadjuvant Chemoradiation in Patients With Adenocarcinoma of the Esophagus” (ESOPEC) (NCT02509286), comparing peri-operative 5-fluorouracil (5-FU), leucovorin, oxaliplatin, docetaxel (FLOT) with CROSS protocol. The second is “NEOAdjuvant Trial in Adenocarcinoma of the oEsophagus and oesophagoGastric Junction Internaional Study” (Neo-AEGIS) which is comparing the MAGIC regimen [peri-operative epirubicin, cisplatin, and 5-FU (ECF)] with CROSS regimen (NCT01726452). The third compares three different arms, pre-operative CF versus peri-operative doce-taxel, cisplatin, and 5-FU (DCF) versus radiotherapy with CF (JCOG1109, NExT study). Results of these studies are awaited.

Preoperative approaches should be considered for localized EAC (Table 1). If surgery is done first, there may be a role for postoperative adjuvant chemoradiation particularly, if surgery was suboptimal.

Definitive chemoradiation is often used for esophageal squamous cell carcinoma. However, long-term results of a phase II study demonstrated favorable results in patients including EAC. Definitive chemoradiation is an option for inoperable EAC or when patients decline surgery.

### Options for localized gastric adenocarcinoma

Complete resection with extended lymph node dissection in a high-volume center provides best outcome for localized gastric adenocarcinoma (GAC). The number of involved lymph nodes determines prognosis and at least fifteen nodes should be removed/examined. Despite the advances in surgical techniques, locoregional and distant recurrence rates remain high and survival rates remain low for localized GAC. By aiming to reduce recurrence rates, several different approaches have been studied.

Initial small studies failed to show benefit. An adjuvant chemoradiation study conducted by MacDonald et al. [Southwest Oncology Group (SWOG) 9008/Intergroup trial 0116 (INT-0116)] accrued a total of 556 patients and randomized to observation after surgery or adjuvant chemoradiation. The relapse rate was higher in the observation group compared to the adjuvant therapy group (\( HR, 1.52; \) 95% CI: 1.23–1.86; \( P < 0.001 \)). The median duration of OS (36 months for adjuvant treatment group vs. 27 months for surgery-only group) and relapse-free survival (RFS) (30 months for adjuvant treatment group vs. 19 months...
for surgery-only group) was longer in adjuvant therapy group. However, Grade 3–4 toxic effects were seen in 73% of patients in adjuvant therapy arm and only 64% of patients completed the treatment as planned. Despite the high toxicity rate, adjuvant chemoradiation has been a standard for resected GAC in the West. Only 10% of enrolled patients had a D2 dissection and the effect of adjuvant radiotherapy in D2 dissected patients was unclear. The phase III trial comparing capcitabine plus cisplatin versus capcitabine plus cisplatin with concurrent capcitabine-radiotherapy in completely resected GAC with D2 lymph node dissection [Adjuvant Chemoradiation Therapy in Stomach Cancer (ARTIST) trial] was designed to clarify that situation. The 5-year OS rates were not different between adjuvant chemoradiation and adjuvant chemotherapy arms and results demonstrated that adjuvant radiation therapy is not effective in D2 dissected patients. The ongoing phase III ARTIST-II trial is comparing adjuvant chemotherapy with chemoradiation in D2 dissected patients with positive lymph nodes (NCT01761461). Recent adjuvant chemotherapy trials from Asia also supported the beneficial effects of adjuvant chemotherapy in patients that underwent D2 dissection and this approach is accepted as a preferable choice for D2 dissected patients.

Response to preoperative chemotherapy was shown to be an important predictor of OS for resectable GAC. “Peri-operative Chemotherapy versus Surgery Alone for Resectable Gastroesophageal Cancer” [Medical Research Council Adjuvant Gastric Infusional Chemotherapy (MAGIC) trial compared peri-operative ECF (epirubicin, cisplatin, and 5-FU) regimen to surgery alone. An estimated improvement of 13% points in the 5-year survival rate with 36.3% and 23.0% for peri-operative treatment and surgery-only groups was reported; however, these outcomes are very poor for both arms. Additionally, less than 50% of patients could complete post-operative treatment. Since the MAGIC trial, ECF has been standard of care in Europe for resectable GAC. In FLOT4-AIO phase III trial, Al-Batran et al noted an increased rate of R0 surgery and prolonged PFS (18 months for ECF vs. 30 months for FLOT; HR, 0.75; 95% CI: 0.62–0.91; P = 0.004) and OS (35 months for ECF vs. 50 months for FLOT; HR, 0.77; 95% CI: 0.63–0.94; P = 0.012) for peri-operative FLOT compared to peri-operative ECF. However, FLOT is a toxic regimen and not recommended for every patient. FLOT results are also not mature. Only very fit patients may be offered this regimen and close monitoring is recommended.

In another study, the addition of bevacizumab, that binds to vascular endothelial growth factor (VEGF), to peri-operative ECX for localized GEAC patients was studied but no benefit was noted (3-year OS rate, 50.3% in ECX alone group and 48.1% for ECX plus...
bevacizumab group; HR, 1.09; 95% CI: 0.91–1.29; P = 0.36. More than 70% of all patients could receive post-operative therapies but wound healing complications were more prevalent in bevacizumab group (12% vs. 7%). The phase III studies evaluating adjunctive therapies in resectable GAC are listed in Table 2.

The US SWOG 9008/INT-0116 trial and European MAGIC trial have generated two accepted adjunctive modalities for localized GAC.\textsuperscript{31,47} Adjuvant chemoradiation is falling out of favor and ECF or its modification should be abandoned entirely in favor of 5-FU, oxaliplatin, and leucovorin (FOLFOX).\textsuperscript{3} The first randomized study comparing pre-operative RT with surgery alone, demonstrated significant benefit in resection rates and OS time in favor of the pre-operative radiotherapy arm.\textsuperscript{50} In Phase II trial of pre-operative chemoradiation in patients with localized GAC (RTOG 9904), induction chemotherapy and chemoradiation were applied before gastric surgery.\textsuperscript{51} The reported pathologic complete remission rate was 26% and R0 resection rate was 77%. Another phase II trial with pre-operative chemotherapy with irinotecan and cisplatin followed by concurrent chemoradiation supported the RTOG 9904 trial with a 65% R0 resection rate.\textsuperscript{52} “The Neoadjuvant Chemotherapy Compared With Surgery Alone for Locally Advanced Cancer of the Stomach and Cardia” [European Organisation for Research and Treatment of Cancer (EORTC) 40954] trial intended to evaluate the value of purely pre-operative chemotherapy with CF for resectable GAC.\textsuperscript{53} The trial was closed early due to poor accrual and there was no survival benefit for pre-operative treatment. Two prospective trials are evaluating the role of preoperative chemoradiation in GAC. Trial of “Preoperative Therapy for Gastric and Esophagogastric Junction Adenocarcinoma” (TOPGEAR) (NCT01924819) is a phase III trial comparing peri-operative ECF alone with pre-operative chemoradiation. The interim analysis of first 120 patients demonstrated that pre-operative chemoradiation can be safely applied to patients.\textsuperscript{54} The Multicentric Randomised Trial for Resectable Gastric Cancer (CRITICS II) is a phase II trial comparing three investigational pre-operative treatment arms for resectable GAC (chemotherapy vs. chemotherapy and subsequent chemoradiotherapy vs. chemoradiotherapy) (NCT02931890). The results of TOPGEAR study with the outcome of CRITICS II study will determine the optimal adjunctive approach for resectable GAC.

### Approaches for unresectable gastroesophageal adenocarcinoma

GEACs are mostly diagnosed at advanced stage and the estimated 5-year relative survival rate at this stage is about 5%.\textsuperscript{55,56} Although cure is not possible, systemic therapy can palliate symptoms, improve survival

| Table 2 |
|-------------|-----------------|-----------------|
| **Trial** | **Arms** | **n** | **Outcome** |
| SWOG 9008/INT-0116\textsuperscript{11} | Surgery vs. surgery → CRT | 275 vs. 281 | 3-year OS rate, 41% vs. 50%; HR, 1.35; 95% CI: 1.09–1.66; P = 0.005 |
| ARTIST\textsuperscript{32} | Surgery (D2) → CT vs. surgery (D2) → CRT | 228 vs. 230 | 5-year OS rate, 73% vs. 75%; HR, 1.130; 95% CI: 0.775–1.647; P = 0.5272 |
| ACTS GC\textsuperscript{43,44} | Surgery (D2) vs. surgery (D2) → S1 | 530 vs. 529 | 3-year OS rate, 70.1% vs. 80.1%; HR, 0.68; 95% CI: 0.52–0.87; P = 0.003 |
| CLASSIC\textsuperscript{45} | Surgery (D2) vs. surgery (D2) → XELOX | 520 vs. 515 | 5-year OS rate, 69% vs. 78%; HR, 0.66; 95% CI: 0.51–0.85; P = 0.0015 |
| MAGIC\textsuperscript{47} | Surgery vs. ECF×3 → surgery → ECF×3 | 253 vs. 250 | 5-year OS rate, 23.0% vs. 36.3%; HR, 0.75; 95% CI: 0.60–0.93; P = 0.009 |
| FLOT4-AIO\textsuperscript{48} | FLOT×4 → surgery → FLOT×4 vs. ECF×3 → surgery → ECF×3 | 356 vs. 360 | 5-year OS rate, 45% vs. 36%; HR, 0.77; 95% CI: 0.63–0.94; P = 0.012 |
| ST03\textsuperscript{49} | (ECX + bevacizumab)×3 → surgery → (ECX + bevacizumab)×3 vs. ECX×3 → surgery → ECX×3 | 533 vs. 530 | 3-year OS rate, 48.1% vs. 50.3%; HR, 1.09; 95% CI: 0.91–1.29; P = 0.36 |

SWOG 9008/INT-0116: Southwest Oncology Group 9008/Intergroup trial 0116; CRT: chemoradiation therapy; OS: overall survival; HR: hazard ratio; CI: confidence interval; ARTIST: Adjuvant Chemoradiation Therapy in Stomach Cancer; CT: chemotherapy; ACTS GC: Adjuvant Chemotherapy Trial of S-1 for Gastric Cancer; CLASSIC: Capecitabine and Oxaliplatin Adjuvant Study in Stomach Cancer; XELOX: capecitabine/oxaliplatin; MAGIC: Medical Research Council Adjuvant Gastric Infusional Chemotherapy; ECF: epirubicin, cisplatin, and 5-fluorouracil; FLOT4-AIO: perioperative chemotherapy with docetaxel, oxaliplatin, and fluorouracil/leucovorin (FLOT) versus epirubicin, cisplatin, and fluorouracil or capecitabine (ECF/ECX) for resectable gastric or gastroesophageal junction (GEJ) adenocarcinoma; FLOT: 5-fluorouracil, leucovorin, oxaliplatin, and docetaxel; ECX: epirubicin, cisplatin, and capecitabine; ST03: Chemotherapy With or Without Bevacizumab or Lapatinib to Treat Operable Oesophagogastric Cancer.
and provide a better quality of life compared to the best supportive care.\textsuperscript{57} Local consolidative therapies can be effective in a selected patient group after controlling the disease with extended (not less than 3 months) systemic treatment.\textsuperscript{58}

Chemotherapy regimens including fluoropyrimidines and platinum derivatives are the most investigated combinations and are recommended as the first-line therapy by different guidelines.\textsuperscript{4,59,60} In Western countries, 5-FU or capecitabine is the most commonly used fluoropyrimidines and two consecutive phase III studies showed that capecitabine is as effective as 5-FU in treating GEACs.\textsuperscript{61,62} In Asian countries, S-1 which contains tegafur (a prodrug of 5-FU) has been the most popular companion to platinum derivates after “S-1 plus cisplatin versus S-1 alone for first-line treatment of advanced gastric cancer (SPIRITS)” trial.\textsuperscript{63} However, S-1 did not show the superiority to FU in western GEAC patients in the First-Line Advanced Gastric Cancer Study (FLAGS) trial.\textsuperscript{64}

Oxaliplatin is equal to cisplatin in the first-line treatment of advanced stage GEAC patients with a better safety profile.\textsuperscript{65,66} Today, oxaliplatin most often accompanies to fluoropyrimidines in the first-line treatment of advanced GEAC.

In a phase III study from Europe, irinotecan combined with 5-FU and folinic acid (FOLFIRI) compared to standard CF combination and FOLFIRI was defined as a safe first-line treatment option that can be applied to patients who cannot tolerate platinum compounds.\textsuperscript{67}

Adding a third cytotoxic agent to fluoropyrimidine and platinum derivate combination in the first-line setting does not seem beneficial. In the V325 study, adding docetaxel to cisplatin and 5-FU combination (DCF) ended up with less than 1 month prolongation in OS (9.2 months for DCF vs. 8.6 months for CF; \textit{HR}, 1.29; 95\% \textit{CI}: 1.0–1.6; \textit{P} = 0.02) with 82\% grade 3–4 neutropenia rate in docetaxel arm.\textsuperscript{68} Anthracyclines are not very effective for GEACs and toxicity rate is very high which is not bearable for this patient group.\textsuperscript{69}

So far, the only established target for the first-line treatment of advanced GEAC is human epidermal growth factor receptor 2 (HER2). In “Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal cancer [Trastuzumab for Gastric Cancer (ToGA)]” phase III trial, adding trastuzumab to standard fluoropyrimidine plus platinum combination in HER2 expressing advanced GEAC patients was evaluated.\textsuperscript{70} The median OS was 13.8 months in trastuzumab plus chemotherapy arm and 11.1 months in only chemotherapy arm (\textit{HR}, 0.74; 95\% \textit{CI}: 0.60–0.91; \textit{P} = 0.0046). Today, trastuzumab is a standard component of first-line treatment of HER2 expressing advanced GEACs. Other agents targeting HER2,\textsuperscript{71} epidermal growth factor receptor (EGFR),\textsuperscript{72,73} vascular endothelial growth factor (VEGF),\textsuperscript{74,75} and MET/hepatocyte growth factor (HGF)\textsuperscript{76,77} did not show any beneficial effect in first-line treatment of advanced GEAC.

For the second-line treatment of GEACs, ramucirumab and paclitaxel combination is the best option for today. Ramucirumab is a fully human immunoglobulin G1 (IgG1) monoclonal antibody against vascular endothelial growth factor receptor 2 (VEGFR-2). In “Ramucirumab plus paclitaxel versus placebo plus paclitaxel in patients with previously treated advanced gastric or gastro-oesophageal junction adenocarcinoma (RAINBOW)” trial, ramucirumab plus paclitaxel combination was compared with paclitaxel plus placebo after progression on first line therapy.\textsuperscript{78} The median OS was 9.6 months in ramucirumab arm and 7.4 months in placebo arm (\textit{HR}, 0.807; 95\% \textit{CI}: 0.678–0.962; \textit{P} = 0.017).

A recent report showed that for advanced stage GEAC patients who can tolerate further treatment, third-line and beyond treatments can improve survival.\textsuperscript{79} Irinotecan can be a preferable option for the third-line treatment with a response rate similar to taxanes for advanced stage GEACs.\textsuperscript{80} A novel VEGFR-2 tyrosine kinase inhibitor apatinib is also an option that showed significantly improved OS compared to placebo in an Asian patient population.\textsuperscript{81} Another and more promising option is immunotherapy which can provide more durable responses. Early phase studies did not show any significant activity of ipilimumab [an anti-cytotoxic T-lymphocyte-associated protein 4 (CTLA-4) antibody] on advanced stage GEACs.\textsuperscript{82,83} However, anti-programmed death 1 (PD-1) antibody pembrolizumab resulted in a 22\% response rate in patients with programmed death ligand 1 (PD-L1)-positive GEACs in KEYNOTE-012 phase 1b study.\textsuperscript{84} Phase 1/2 CheckMate-032 study demonstrated a 26\% overall response rate with nivolumab (anti-PD-1 antibody) and ipilimumab combination.\textsuperscript{85} Recently, Kang et al\textsuperscript{86} reported the results of phase III “Nivolumab in patients with advanced gastric or gastro-oesophageal junction cancer refractory to, or intolerant of, at least two previous chemotherapy regimens” (ONO-4538-12, ATTRACTION-2) trial. In this heavily pre-treated Asian patient group, the median OS was longer in nivolumab arm compared to placebo (5.26 months in the nivolumab group and 4.14 months in the placebo group; \textit{HR}, 0.63; 95\% \textit{CI}: 0.51–0.78; \textit{P} < 0.0001). In the subset analysis by PD-L1 expression, they demonstrated that benefit is irrespective of PD-L1 expression.\textsuperscript{87} Outcomes of key studies for advanced stage GEAC are listed in Table 3.
### Table 3
Outcomes of key studies evaluating the right therapy for advanced gastroesophageal adenocarcinoma in different lines.

| Trial/line | Arms | n | Outcome |
|------------|------|---|---------|
| Cunningham et al61/first line | ECF vs. ECX vs. EOF vs. EOX | 1002 | Median OS, 9.9 vs. 9.9 vs. 9.3 vs. 11.2 months; *P* > 0.05 |
| Kang et al62/first line | XP vs. FP | 316 | Median OS, 10.5 vs. 9.3 months; HR, 0.85; 95% CI: 0.64–1.13; *P* = 0.008 |
| Koizumi et al63/first line | S1+cisplatin vs. S1 | 305 | Median OS, 13 vs. 11 months; HR, 0.77; 95% CI: 0.61–0.98; *P* = 0.04 |
| Al-Batran et al65/first line | FLO vs. FLP | 220 | Median OS, 10.7 vs. 8.8 months; *P* > 0.05 |
| Dank et al67/first line | IF vs. CF | 333 | Median OS, 9 vs. 8.7 months; HR, 1.08; 95% CI: 0.86–1.35; *P* = 0.53 |
| Van Cutsem et al62/first line | DCF vs. CF | 445 | Median OS, 9.2 vs. 8.6 months; HR, 1.29; 95% CI: 1.0–1.6; *P* = 0.02 |
| Guimbaud et al69/first line | ECX vs. FOLFIRI | 416 | Median OS, 9.5 vs. 9.7 months; HR, 1.01; 95% CI: 0.82–1.14; *P* = 0.95 |
| Bang et al70/first line | Trastuzumab + CF vs. CF | 594 | Median OS, 13.8 vs. 11.1 months; HR, 0.74; 95% CI: 0.60–0.91; *P* = 0.0046 |
| Wilke et al73/second line | Ramucirumab + paclitaxel vs. placebo + paclitaxel | 665 | Median OS, 9.6 vs 7.4 months; HR, 0.807; 95% CI: 0.678–0.962; *P* = 0.017 |
| Hironaka et al80/second line | Paclitaxel vs. irinotecan | 223 | Median OS, 9.5 vs 8.4 months; HR, 1.13; 95% CI: 0.86–1.49; *P* = 0.38 |
| Li et al81/third line and more | Apatinib vs. placebo | 267 | Median OS, 6.5 vs. 4.7 months; HR, 0.709; 95% CI: 0.537–0.937; *P* = 0.0156 |
| Kang et al86/third line and more | Nivolumab vs. placebo | 493 | Median OS, 5.26 vs. 4.14 months; HR, 0.63; 95% CI: 0.51–0.78; *P* < 0.0001 |

ECF: epirubicin, cisplatin, and 5-fluorouracil; ECX: epirubicin, cisplatin, and capecitabine; EOF: epirubicin, oxaliplatin, and 5-fluorouracil; EOX: epirubicin, oxaliplatin, and capecitabine; OS: overall survival; XP: capecitabine and cisplatin; FP: 5-fluorouracil and cisplatin; HR: hazard ratio; CI: confidence interval; FLO: 5-fluorouracil, leucovorin, and oxaliplatin; FLP: 5-fluorouracil, leucovorin, and cisplatin; IF: irinotecan and 5-fluorouracil; CF: cisplatin plus 5-fluorouracil; DCF: docetaxel, cisplatin, and 5-fluorouracil; FOLFIRI: 5-fluorouracil, leucovorin, and irinotecan.

Numerous phase III trials evaluating targeted therapies in different lines are ongoing and we will be able to determine the most appropriate patient group that can benefit from various targeted agents and immunotherapy in the future.

### Conflicts of interest

The authors have no conflicts of interest to declare.

### References

1. Torre LA, Siegel RL, Ward EM, Jemal A. Global cancer incidence and mortality rates and trends—an update. *Cancer Epidemiol Biomark Prev*. 2016;25:16–27.
2. Blot WJ, Devesa SS, Kneller RW, Fraumeni JF. Rising incidence of adenocarcinoma of the esophagus and gastric cardia. *JAMA*. 1991;265:1287–1289.
3. Ajani JA, D’Amico TA, Almhanna K, et al. Esophageal and esophagogastric junction cancers, version 2.2015. *J Natl Compr Canc Netw*. 2015;13:194–227.
4. Ajani JA, D’Amico TA, Almhanna K, et al. Gastric cancer, version 3.2016, NCCN clinical practice guidelines in Oncology. *J Natl Compr Canc Netw*. 2016;14:1286–1312.
5. Nie S, Chen T, Yang X, Huai P, Lu M. Association of Helicobacter pylori infection with esophageal adenocarcinoma and squamous cell carcinoma: a meta-analysis. *Dis Esophagus*. 2014;27:645–653.
6. Kamangar F, Dawsey SM, Blaser MJ, et al. Opposing risks of gastric cardia and noncardia gastric adenocarcinomas associated with Helicobacter pylori seropositivity. *J Natl Cancer Inst*. 2006;98:1445–1452.
7. Esophagus and esophagogastric junction. In: Amin MB, Edge S, Greene F, et al., eds. *AJCC Cancer Staging Manual*. 8th ed. Cham, Switzerland: Springer International Publishing; 2017:185–202.
8. Choi KS, Jung HY, Choi KD, et al. EMR versus gastrectomy for intramucosal gastric cancer: comparison of long-term outcomes. *Gastrointest Endosc*. 2011;73:942–948.
9. Oda I, Saito D, Tada M, et al. A multicenter retrospective study of endoscopic resection for early gastric cancer. *Gastric Cancer*. 2006;9:262–270.
10. Kelsen DP, Ginsberg R, Pajak TF, et al. Chemotherapy followed by surgery compared with surgery alone for localized esophageal cancer. *N Engl J Med*. 1998;339:1979–1984.
11. Medical Research Council Oesophageal Cancer Working Group. Surgical resection with or without preoperative chemotherapy in oesophageal cancer: a randomised controlled trial. *Lancet*. 2002;359:1727–1733.
12. Chirieac LR, Swisher SG, Ajani JA, et al. Posttherapy pathologic stage predicts survival in patients with esophageal carcinoma receiving preoperative chemoradiation. *Cancer*. 2005;103:1347–1355.
13. Kelsen DP, Winter KA, Gunderson LL, et al. Long-term results of RTOG trial 8911 (USA Intergroup 113): a random assignment trial comparison of chemotherapy followed by surgery compared with surgery alone for esophageal cancer. *J Clin Oncol*. 2007;25:3719–3725.
24. Stahl M, Walz MK, Stuschke M, et al. Phase III comparison of chemoradiotherapy versus surgery alone for resectable gastroesophageal adenocarcinoma: a randomised controlled trial. *J Clin Oncol*. 2011;29:1715–1721.

25. Stahl M, Walz MK, Riera-Knorrenschild J, et al. Preoperative chemoradiotherapy compared with surgery alone for resectable gastroesophageal adenocarcinoma: an ENCLCC and FFCD multicenter phase III trial. *J Clin Oncol*. 2011;29:1715–1721.

26. Ychou M, Boige V, Pignon JP, et al. Perioperative chemotherapy compared with surgery alone for resectable gastroesophageal adenocarcinoma: a randomised controlled phase III trial. *J Clin Oncol*. 2011;29:1715–1721.

27. Walsh TN, Noonan N, Hollywood D, Kelly A, Keeling N, Hennessy TP. A comparison of multimodal therapy and surgery for esophageal adenocarcinoma. *N Engl J Med*. 1996;335:462–467.

28. Urba SG, Orringer MB, Turrisi A, Iannettoni M, Forastiere A, Simes J. Survival benefits from neoadjuvant chemoradiotherapy for esophageal or junctional cancer. *Gut*. 2004;53:925–930.

29. Nakamura K, Kato K, Igaki H, et al. Three-arm phase III trial comparing cisplatin plus 5-FU (CF) versus docetaxel, cisplatin plus 5-FU (DCF) versus radiotherapy with CF (CF-RT) as preoperative therapy for locally advanced esophageal cancer (JCOG1109, NEJ03 study). *Jpn J Clin Oncol*. 2013;43:752–755.

30. Adelstein DJ, Rice TW, Rybicki LA, et al. Mature results from a phase II trial of postoperative concurrent chemoradiotherapy for poor prognosis cancer of the esophagus and gastroesophageal junction. *J Thorac Oncol*. 2009;4:1264–1269.

31. Macdonald JS, Smalley SR, Benedetti J, et al. Chemoradiotherapy after surgery compared with surgery alone for adenocarcinoma of the stomach or gastroesophageal junction. *N Engl J Med*. 2001;345:725–730.

32. Conroy T, Galais MP, Raoul JL, et al. Definitive chemoradiotherapy with FOLFOX versus fluorouracil and cisplatin in patients with oesophageal cancer (PRODIGE/ACCORD17): final results of a randomised, phase 2/3 trial. *Lancet Oncol*. 2014;15:305–314.

33. Swisher SG, Moughan J, Komaki RU, et al. Final results of NRG Oncology RTOG 0246: an organ-preserving selective resection strategy in esophageal cancer patients treated with definitive chemoradiation. *J Thorac Oncol*. 2017;12:368–374.

34. Ajani JA, Lee J, Sano T, Janjigian YY, Fan D, Song S. Gastric adenocarcinoma. *Nat Rev Dis Primers*. 2017;3:17036.

35. Enzinger PC, Benedetti JK, Meyerhardt JA, et al. Impact of hospital volume on recurrence and survival after surgery for gastric cancer. *Ann Surg*. 2007;245:426–434.

36. Karpeh MS, Leon L, Klimstra D, Brennan MF. Lymph node staging in gastric cancer: is location more important than Number? An analysis of 1,038 patients. *Ann Surg*. 2000;232:362–371.

37. Hallissey MT, Dunn JA, Ward LC, Allum WH. The second British Stomach Cancer Group trial of adjuvant radiotherapy or chemotherapy in resectable gastric cancer: five-year follow-up. *Lancet*. 1994;343:1309–1312.

38. Nashimoto A, Nakajima T, Furukawa H, et al. Randomized trial of adjuvant chemotherapy with mitomycin, Fluorouracil, and Cytosine arabinoside followed by oral Fluorouracil in serosal-negative gastric cancer: Japan Clinical Oncology Group 9206-1. *J Clin Oncol*. 2003;21:2282–2287.

39. Bouché O, Ychou M, Burtin P, et al. Adjuvant chemotherapy with 5-fluorouracil and cisplatin compared with surgery alone for gastric cancer: 7-year results of the FFCD randomized phase III trial (8801). *Ann Oncol*. 2005;16:1488–1497.

40. De Vita F, Giuliani F, Orditura M, et al. Adjuvant chemotherapy with epirubicin, leucovorin, 5-fluorouracil and etoposide regimen in resected gastric cancer patients: a randomized phase III trial by the Group Oncologico Italia Meridionale (GOIM 9602 Study). *Ann Oncol*. 2007;18:1354–1358.

41. Lee J, Lim DH, Kim S, et al. Phase III trial comparing capecitabine plus cisplatin versus capecitabine plus cisplatin with concurrent capecitabine radiotherapy in completely resected gastric cancer with D2 lymph node dissection: the ARTIST trial. *J Clin Oncol*. 2012;30:268–273.

42. Park SH, Sohn TS, Lee J, et al. Phase III trial to compare adjuvant chemotherapy with capecitabine and cisplatin versus concurrent chemoradiotherapy in gastric cancer: final report of the adjuvant chemoradiotherapy in stomach tumors trial, including survival and subset analyses. *J Clin Oncol*. 2015;33:3130–3136.

43. Sakuramoto S, Sasaki M, Yamaguchi T, et al. Adjuvant chemotherapy for gastric cancer with S-1, an oral fluoropyrimidine. *N Engl J Med*. 2007;357:1810–1820.

44. Sasaki M, Sakuramoto S, Katai H, et al. Five-year outcomes of a randomized phase III trial comparing adjuvant chemotherapy with S-1 versus surgery alone in stage II or III gastric cancer. *J Clin Oncol*. 2011;29:4387–4393.
54. Leong T, Smithers BM, Haustermans K, et al. TOPGEAR: a randomized phase 3 FLOT4-AIO trial (German Gastric Group at AIO). Ann Oncol. 2017;28(suppl 5):v605–v649.

55. Schuhmacher C, Gretschel S, Lordick F, et al. Neoadjuvant chemotherapy versus surgery alone for resectable gastroesophageal cancer. N Engl J Med. 2006;355:11–20.

56. Al-Batran SE, Hartmann JT, Probst S, et al. Phase III trial in metastatic gastroesophageal adenocarcinoma with fluorouracil, leucovorin plus either oxaliplatin or cisplatin: a study of the Arbeitsgemeinschaft Internistische Onkologie. J Clin Oncol. 2008;26:1435–1442.

57. Dank M, Zaluski J, Barone C, et al. Randomized phase III study comparing irinotecan combined with 5-fluorouracil and folinic acid to cisplatin combined with 5-fluorouracil in chemotherapy naive patients with advanced adenocarcinoma of the stomach or esophagogastrectomy junction. Ann Oncol. 2008;19:1450–1457.

58. Van Cutsem E, Moiseyenko VM, Tjulandin S, et al. Phase III study of docetaxel and cisplatin plus fluorouracil compared with cisplatin and fluorouracil as first-line therapy for advanced gastric cancer: a report of the V325 Study Group. J Clin Oncol. 2006;24:4991–4997.

59. Guimbaud R, Louvet C, Ries P, et al. Prospective, randomized, multicenter, phase III study of fluorouracil, leucovorin, and irinotecan versus epirubicin, cisplatin, and capecitabine in advanced gastric adenocarcinoma: a French intergroup (Fédération Francophone de Cancérologie Digestive, Fédération Nationale des Centres de Lutte Contre le Cancer, and Groupe Coopérateur Multidisciplinaire en Oncologie) study. J Clin Oncol. 2014;32:3520–3526.

60. Japanese Gastric Cancer Association. Japanese gastric cancer treatment guidelines 2014 (ver. 4). Gastric Cancer. 2017;20:1–19.
74. Ohtsu A, Shah MA, Van Cutsem E, et al. Bevacizumab in combination with chemotherapy as first-line therapy in advanced gastric cancer: a randomized, double-blind, placebo-controlled phase III study. J Clin Oncol. 2011;29:3968–3976.
75. Shen L, Li J, Xu J, et al. Bevacizumab plus capcitabine and cisplatin in Chinese patients with inoperable locally advanced or metastatic gastric or gastroesophageal junction cancer: randomized, double-blind, phase III study (AVATAR study). Gastric Cancer. 2015;18:168–176.
76. Cunningham D, Tebbutt NC, Davidenko I, et al. Phase III, randomized, double-blind, multicenter, placebo (P)-controlled trial of rilotumumab (R) plus epirubicin, cisplatin and capcitabine (ECX) as first-line therapy in patients (pts) with advanced MET-positive (pos) gastric or gastroesophageal junction (G/GEJ) cancer: RILOMET-1 study. J Clin Oncol. 2015;33(15 Suppl):4000.
77. Doi T, Kang YK, Muro K, Jiang Y, Jain RK, Lizambri R. A phase 3, multicenter, randomized, double-blind, placebo-controlled study of rilotumumab in combination with cisplatin and capcitabine (CX) as first-line therapy for Asian patients (pts) with advanced MET-positive gastric or gastroesophageal junction (G/GEJ) adenocarcinoma: The RILOMET-2 trial. J Clin Oncol. 2015;33(3 Suppl):TPS226.
78. Wilke H, Muro K, Van Cutsem E, et al. Ramucirumab plus paclitaxel versus placebo plus paclitaxel in patients with previously treated advanced gastric or gastro-oesophageal junction adenocarcinoma (RAINBOW): a double-blind, randomised phase 3 trial. Lancet Oncol. 2014;15:1224–1235.
79. Cafferkey C, Davidson M, Goode E, et al. Survival in advanced oesophagogastric adenocarcinoma (OGA) improves with the use of multiple lines of therapy: Results from an analysis of over 500 patients (pts). Ann Oncol. 2017;28(suppl 5):v209–v268.
80. Hironaka S, Ueda S, Yasui H, et al. Randomized, open-label, phase III study comparing irinotecan with paclitaxel in patients with advanced gastric cancer without severe peritoneal metastasis after failure of prior combination chemotherapy using fluoropyrimidine plus platinum: WJOG 4007 trial. J Clin Oncol. 2013;31:4438–4444.
81. Li J, Qin S, Xu J, et al. Randomized, double-blind, placebo-controlled phase III trial of apatinib in patients with chemotherapy-refractory advanced or metastatic adenocarcinoma of the stomach or gastroesophageal junction. J Clin Oncol. 2016;34:1448–1454.
82. Ralph C, Elkord E, Burt DJ, et al. Modulation of lymphocyte regulation for cancer therapy: a phase II trial of tremelimumab in advanced gastric and esophageal adenocarcinoma. Clin Cancer Res. 2010;16:1662–1672.
83. Mochler MH, Cho JY, Kim YH, et al. A randomized, open-label, two-arm phase II trial comparing the efficacy of sequential ipilimumab (ipi) versus best supportive care (BSC) following first-line (1L) chemotherapy in patients with unresectable, locally advanced/metastatic (A/M) gastric or gastro-esophageal junction (G/GEJ) cancer. J Clin Oncol. 2016;34(15 Suppl):4011.
84. Muro K, Chung HC, Shankaran V, et al. Pembrolizumab for patients with PD-L1-positive advanced gastric cancer (KEYNOTE-012): a multicentre, open-label, phase I/II trial. Lancet Oncol. 2016;17:717–726.
85. Janjigian YY, Bendell JC, Calvo E, et al. CheckMate-032: Phase II, open-label study of safety and activity of nivolumab (nivo) alone or with ipilimumab (ipi) in advanced and metastatic (A/M) gastric cancer (GC). J Clin Oncol. 2016;34(15 Suppl):4010.
86. Kang YK, Boku N, Satoh T, et al. Nivolumab in patients with advanced gastric or gastro-oesophageal junction cancer refractory to, or intolerant of, at least two previous chemotherapy regimens (ONO-4538–12, ATTRACTION-2): a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet. 2017;390:2461–2471.
87. Boku N, Kang YK, Satoh T, et al. A Phase 3 Study of nivolumab (Nivo) in previously treated advanced gastric or gastroesophageal junction cancer: Updated results and subset analysis by PD-L1 expression (ATTRACTION-02). Ann Oncol. 2017;28(suppl 5):v209–v268.
88. Mizrak Kaya D, Harada K, Ajani JA. Is targeted therapy possible for patients with gastric adenocarcinoma? Expert Opin Pharmacother. 2016;17:2371–2374.

Edited by Pei-Fang Wei